MedTrace Logo

Copeptin for Risk Stratification in Acute Stroke Patients: the CoRisk Study

NCT00878813 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1102

Last updated 2011-11-10

No results posted yet for this study

Summary

Prospective observational multicenter study to evaluate copeptin as a prognostic marker in patients with an acute cerebrovascular event. It includes four groups of patients, mainly depending on type of initial therapy (intra-arterial thrombolysis, intravenous thrombolysis, conservative treatment, TIA). The study takes place at the Emergency and neurological Department of the University of Bern, Switzerland; Department of Neurology, Goethe University of Frankfurt a.M. (Germany). Further participating centers are under discussion

Conditions

  • Stroke
  • Transient Ischemic Attack

Interventions

PROCEDURE

Sampling of 15ml blood

On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling

PROCEDURE

Blood-Sampling

On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.

Sponsors & Collaborators

  • University of Basel

    collaborator OTHER

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Goethe University

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Gian Marco De Marchis, MD · Inselspital, Bern University Hospital

  • Marcel Arnold, MD · Inselspital, Bern University Hospital

  • Mira Katan, MD · University Hospital, Basel, Switzerland

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-04-30
Completion
2011-10-31

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00878813 on ClinicalTrials.gov